Across TCGA pan-cancer cohorts, COMMD8 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated COMMD8 data layer compared with 22 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in stomach adenocarcinoma (STAD), where higher COMMD8 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated COMMD8 expression acts as an unfavorable survival marker.
STAD, PRAD, and SKCM are the cancer types where COMMD8 Mutation most reproducibly stratifies survival.